You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 7, 2025

Journey Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Journey
International Patents:89
US Patents:32
Tradenames:7
Ingredients:4
NDAs:9
Patent Litigation for Journey: See patent lawsuits for Journey

Drugs and US Patents for Journey

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Journey ZILXI minocycline hydrochloride AEROSOL, FOAM;TOPICAL 213690-001 May 28, 2020 RX Yes Yes 8,992,896 ⤷  Try for Free Y ⤷  Try for Free
Journey EURAX crotamiton LOTION;TOPICAL 009112-003 Approved Prior to Jan 1, 1982 AT RX Yes Yes ⤷  Try for Free ⤷  Try for Free
Journey AMZEEQ minocycline hydrochloride AEROSOL, FOAM;TOPICAL 212379-001 Oct 18, 2019 RX Yes Yes 9,675,700 ⤷  Try for Free Y ⤷  Try for Free
Journey AMZEEQ minocycline hydrochloride AEROSOL, FOAM;TOPICAL 212379-001 Oct 18, 2019 RX Yes Yes 10,213,512 ⤷  Try for Free Y ⤷  Try for Free
Journey ZILXI minocycline hydrochloride AEROSOL, FOAM;TOPICAL 213690-001 May 28, 2020 RX Yes Yes 9,675,700 ⤷  Try for Free Y ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Journey

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Journey XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-001 Jul 11, 2012 5,908,838 ⤷  Try for Free
Journey QBREXZA glycopyrronium tosylate CLOTH;TOPICAL 210361-001 Jun 28, 2018 6,433,003 ⤷  Try for Free
Journey XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-005 Jul 11, 2012 5,908,838 ⤷  Try for Free
Journey XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-001 Jul 11, 2012 8,268,804 ⤷  Try for Free
Journey XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-001 Jul 11, 2012 8,252,776 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for Journey Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2435024 15/2021 Austria ⤷  Try for Free PRODUCT NAME: FORMOTEROLFUMARAT-DIHYDRAT / GLYCOPYRRONIUMBROMID / BUDESONID; REGISTRATION NO/DATE: EU/1/20/1498 (MITTEILUNG) 20201210
1267866 92393 Luxembourg ⤷  Try for Free PRODUCT NAME: GLYCOPYRRONIUM OU UN SEL DE CELUI-CI, PLUS PARTICULIEREMENT LE SEL BROMURE, COMBINE A INDACATEROL OU UN SEL DE CELUI-CI, PLUS PARTICULIEREMENT LE SEL MALEATE. FIRST REGISTRATION: 20130923
1267866 122014000025 Germany ⤷  Try for Free PRODUCT NAME: GLYCOPYRRONIUM ODER EIN SALZ ODER DERIVAT HIERVON (KOMPONENTE 1) UND INDACATEROL ODER EIN DERIVAT HIERVON ODER EIN SALZ VON INDACATEROL ODER EINEM DERIVAT HIERVON (KOMPONENTE 2); REGISTRATION NO/DATE: EU/1/13/862 20130919
2435024 C02435024/01 Switzerland ⤷  Try for Free PRODUCT NAME: BUDESONID, GLYCOPYRRONIUM UND FORMOTEROL; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 68388 24.11.2021
1267866 SPC/GB13/020 United Kingdom ⤷  Try for Free PRODUCT NAME: GLYCOPYRRONIUM OR A SALT THEREOF; REGISTERED: UK EU/1/12/788/001 20120928; UK EU/1/12/788/002 20120928; UK EU/1/12/788/003 20120928; UK EU/1/12/788/004 20120928; UK EU/1/12/788/005 20120928; UK EU/1/12/788/006 20120928
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Pharmaceutical Competitive Landscape Analysis: Journey – Market Position, Strengths & Strategic Insights

Last updated: February 15, 2025

In the fast-paced world of pharmaceuticals, staying ahead of the competition is not just an advantage – it's a necessity. The pharmaceutical industry is a complex ecosystem where innovation, regulation, and market dynamics intertwine to create a challenging yet opportunity-rich environment. To navigate this landscape successfully, companies must arm themselves with a comprehensive understanding of their competitive position and the forces shaping the industry.

The Evolving Pharmaceutical Landscape

The pharmaceutical market is experiencing unprecedented growth and transformation. According to recent projections, the global pharmaceutical market is expected to reach a staggering USD 2,832.66 billion by 2033, growing at a CAGR of 6.15% from 2024 to 2033[2]. This growth is driven by various factors, including an aging population, increasing prevalence of chronic diseases, and advancements in medical technology.

Key Market Drivers

  1. Rising Chronic Disease Prevalence: The increasing incidence of chronic conditions such as diabetes, cancer, and cardiovascular diseases is fueling demand for innovative treatments.

  2. Aging Population: As the global population ages, there's a growing need for medications to manage age-related health issues.

  3. Healthcare Expenditure: Governments and private entities are investing more in healthcare, boosting the pharmaceutical sector.

  4. Technological Advancements: Breakthroughs in areas like gene therapy and personalized medicine are opening new avenues for drug development.

Understanding Competitive Landscape Analysis

Competitive landscape analysis in the pharmaceutical industry is a strategic tool that helps companies gain a comprehensive understanding of their market position relative to their competitors. It involves a systematic evaluation of competitors' strengths, weaknesses, strategies, and market positioning[5].

Why is Competitive Analysis Crucial?

  1. Identifying Market Opportunities: By understanding what competitors are (and aren't) doing, companies can identify gaps in the market ripe for innovation.

  2. Anticipating Industry Trends: Competitive analysis helps companies stay ahead of emerging trends and prepare for future challenges.

  3. Informing R&D Decisions: In an industry where R&D costs can run into billions, making informed decisions about which projects to pursue is crucial.

"Competitor analysis is not about copying what others are doing. It's about understanding the competitive landscape so you can chart your own unique course to success." – Dr. Jane Smith, Pharmaceutical Strategy Expert[5]

Key Components of Pharmaceutical Competitive Analysis

1. Product Portfolio Analysis

Understanding competitors' product portfolios is crucial. This includes analyzing:

  • Current marketed products
  • Pipeline products
  • Therapeutic areas of focus
  • Innovative technologies being leveraged

2. Financial Performance Evaluation

Analyzing the financial health of competitors provides valuable insights into:

  • R&D investment levels
  • Profitability of key products
  • Strategic priorities

3. Patent Landscape Assessment

In the pharmaceutical industry, patents are the lifeblood of innovation. A thorough patent analysis includes:

  • Competitor patent portfolios
  • Patent expiration dates
  • Potential opportunities and threats arising from patent landscapes

4. Regulatory Strategy Analysis

Understanding how competitors navigate the complex regulatory landscape can provide valuable lessons. This includes analyzing:

  • Approaches to clinical trials
  • Regulatory submission strategies
  • Market access strategies

Tools and Techniques for Effective Analysis

SWOT Analysis

The SWOT (Strengths, Weaknesses, Opportunities, Threats) framework remains a valuable tool in pharmaceutical competitive analysis. It provides a structured way to evaluate both internal and external factors affecting a competitor's market position[7].

Strengths in the Pharmaceutical Industry

  • Strong R&D capabilities
  • Robust intellectual property portfolio
  • Global market presence
  • Regulatory compliance expertise

Weaknesses to Consider

  • Patent expirations
  • High research costs
  • Dependency on few blockbuster drugs
  • Regulatory challenges

Opportunities to Explore

  • Emerging markets expansion
  • Biotechnology collaborations
  • Technological advancements in drug discovery
  • Strategic mergers and acquisitions

Threats to Watch

  • Generic competition
  • Regulatory changes
  • Pricing pressures
  • Product liability risks

Porter's Five Forces

This framework, developed by Michael Porter, helps analyze the competitive intensity and attractiveness of the pharmaceutical industry. It considers:

  1. Bargaining power of suppliers
  2. Bargaining power of buyers
  3. Threat of new entrants
  4. Threat of substitutes
  5. Intensity of competitive rivalry

Benchmarking

Comparing key performance indicators (KPIs) with those of competitors can provide valuable insights. Relevant KPIs in the pharmaceutical industry might include:

  • R&D spend as a percentage of revenue
  • Time-to-market for new products
  • Market share in specific therapeutic areas

Social Media Monitoring

In today's digital age, social media can be a goldmine of competitive intelligence. Monitoring competitors' social media activities can provide insights into:

  • Marketing strategies
  • Product launches
  • Potential issues or challenges they're facing

Market Position Analysis

Understanding your company's market position relative to competitors is crucial for strategic decision-making. This involves analyzing:

Market Share

  • Overall market share
  • Share in specific therapeutic areas or geographic regions

Brand Perception

  • How is your brand perceived compared to competitors?
  • What are your unique selling propositions?

Pricing Strategy

  • How do your prices compare to competitors?
  • What pricing models are being used in the market?

Strengths Assessment

Identifying and leveraging your company's strengths is key to gaining a competitive advantage. Common strengths in the pharmaceutical industry include:

Research and Innovation

The pharmaceutical industry's focus on innovation and research sets it apart from other sectors. Companies invest millions of dollars each year to develop effective medicines[3].

Intellectual Property and Patents

Strong intellectual property protection allows pharmaceutical companies to invest heavily in R&D, knowing their innovations will be protected[3].

Regulatory Expertise

Navigating the complex regulatory landscape is a crucial strength in the pharmaceutical industry. Companies with strong regulatory expertise can bring products to market more efficiently.

Global Reach

A strong global presence allows pharmaceutical companies to tap into diverse markets and spread risk across different regions.

Strategic Insights for Market Domination

Armed with a comprehensive competitive landscape analysis, pharmaceutical companies can develop strategies to strengthen their market position and drive growth.

1. Focus on Unmet Medical Needs

Identifying and addressing unmet medical needs can provide significant opportunities for growth. This might involve:

  • Developing treatments for rare diseases
  • Improving existing therapies for better efficacy or fewer side effects
  • Addressing neglected diseases in developing markets

2. Embrace Digital Transformation

Leveraging digital technologies can provide a competitive edge. This might include:

  • Implementing AI and machine learning in drug discovery
  • Using big data analytics for clinical trial optimization
  • Developing digital therapeutics to complement traditional treatments

3. Pursue Strategic Partnerships

Collaborations can help pharmaceutical companies access new technologies, markets, or expertise. Consider:

  • Partnerships with biotech companies for innovative drug development
  • Collaborations with tech companies for digital health solutions
  • Alliances with academic institutions for early-stage research

4. Optimize Product Lifecycle Management

Effective lifecycle management can help maximize the value of existing products. Strategies might include:

  • Developing new formulations or delivery methods
  • Expanding indications for existing drugs
  • Implementing robust patent protection strategies

5. Enhance Market Access Strategies

In an increasingly cost-conscious healthcare environment, effective market access strategies are crucial. This might involve:

  • Developing value-based pricing models
  • Engaging with payers early in the drug development process
  • Demonstrating real-world evidence of treatment efficacy and cost-effectiveness

Case Studies: Competitive Analysis in Action

Pfizer's COVID-19 Vaccine Strategy

When the COVID-19 pandemic hit, Pfizer quickly analyzed the competitive landscape and identified an opportunity to partner with BioNTech to develop an mRNA vaccine. This strategic move, informed by competitor analysis, allowed Pfizer to become one of the first companies to bring a COVID-19 vaccine to market[5].

Gilead's Hepatitis C Strategy

Gilead's success in the Hepatitis C market is a testament to effective competitor analysis. By closely monitoring the competition and identifying gaps in the market, Gilead was able to develop and launch highly effective treatments that revolutionized Hepatitis C care[5].

The Future of Pharmaceutical Competitive Analysis

As we look to the future, several trends are likely to shape the landscape of pharmaceutical competitive analysis:

Increased Use of AI and Machine Learning

AI and ML will play an increasingly important role in analyzing vast amounts of data to derive competitive insights. This might include:

  • Predictive analytics for market trends
  • Automated patent landscape analysis
  • Real-time monitoring of competitor activities

Greater Focus on Patient-Centric Metrics

As the industry moves towards more patient-centric models, competitive analysis will likely focus more on:

  • Patient-reported outcomes
  • Real-world evidence of treatment efficacy
  • Patient engagement and adherence metrics

Integration with Strategic Planning

Competitive analysis will become more tightly integrated with strategic planning processes, informing decisions at the highest levels of pharmaceutical organizations. This might involve:

  • Real-time competitive intelligence dashboards for executives
  • Scenario planning based on competitive landscape analysis
  • Agile strategy development in response to competitive shifts

Key Takeaways

  • The global pharmaceutical market is projected to reach USD 2,832.66 billion by 2033, growing at a CAGR of 6.15%.
  • Competitive landscape analysis is crucial for identifying market opportunities, anticipating trends, and informing R&D decisions.
  • Key components of analysis include product portfolio analysis, financial performance evaluation, patent landscape assessment, and regulatory strategy analysis.
  • Tools like SWOT analysis, Porter's Five Forces, and AI-driven analytics can enhance competitive intelligence efforts.
  • Strategic insights derived from competitive analysis can help companies focus on unmet medical needs, embrace digital transformation, pursue strategic partnerships, optimize product lifecycle management, and enhance market access strategies.
  • The future of pharmaceutical competitive analysis will likely involve increased use of AI, a greater focus on patient-centric metrics, and tighter integration with strategic planning processes.

FAQs

  1. Q: How often should pharmaceutical companies conduct competitive landscape analyses? A: Competitive landscape analysis should be an ongoing process, with formal reviews conducted at least annually or whenever significant market changes occur.

  2. Q: What are some common pitfalls in pharmaceutical competitive analysis? A: Common pitfalls include focusing too narrowly on direct competitors, overlooking emerging technologies or market entrants, and failing to consider regulatory and pricing dynamics.

  3. Q: How can small pharmaceutical companies compete effectively against industry giants? A: Small companies can focus on niche markets, leverage partnerships and collaborations, and prioritize innovation in specific therapeutic areas to compete effectively.

  4. Q: What role does social media play in pharmaceutical competitive analysis? A: Social media can provide valuable insights into competitor marketing strategies, product launches, and public perception, complementing traditional competitive intelligence methods.

  5. Q: How can pharmaceutical companies protect their competitive advantages? A: Companies can protect their advantages through robust patent strategies, continuous innovation, strong brand building, and by fostering a culture of adaptability and customer-centricity.

Sources cited: [1] https://visualping.io/blog/competitive-intelligence-in-pharma [2] https://www.visionresearchreports.com/pharmaceutical-market/41230 [3] https://pestleanalysis.com/pharmaceutical-industry-swot-analysis/ [5] https://www.drugpatentwatch.com/blog/the-importance-of-pharmaceutical-competitor-analysis/ [7] https://www.easyglobaltraining.com/blogs/regulatory-updates-blogs/what-is-strengths-weaknesses-opportunities-and-threats-analysis-in-pharmaceutical-industry/

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.